MG
ABUS icon

Michael Gelband’s Arbutus Biopharma ABUS Stock Holding History

Michael Gelband’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,554
Closed -$106K – 1516
2026
Q1 		$106K Sell
23,554
-6,949
-23% -$30.4K ﹤0.01% 1434
2025
Q4 		$147K Sell
30,503
-51,874
-63% -$233K ﹤0.01% 1417
2025
Q3 		$374K Buy
82,377
+1,302
+2% +$4.78K ﹤0.01% 1249
2025
Q2 		$251K Buy
81,075
+1,575
+2% +$5.23K ﹤0.01% 1273
2025
Q1 		$277K Buy
+79,500
New +$265K ﹤0.01% 1246
2021
Q4 		– Sell
-22,184
Closed -$95K – 2116
2021
Q3 		$95K Buy
+22,184
New +$73.9K ﹤0.01% 1913
2021
Q2 		– Sell
-160,048
Closed -$533K – 2271
2021
Q1 		$533K Buy
160,048
+42,570
+36% +$164K 0.01% 1301
2020
Q4 		$417K Buy
117,478
+104,534
+808% +$366K ﹤0.01% 1356
2020
Q3 		$41K Sell
12,944
-4,056
-24% -$12.3K ﹤0.01% 1641
2020
Q2 		$31K Buy
17,000
+3,131
+23% +$5.12K ﹤0.01% 1698
2020
Q1 		$14K Sell
13,869
-22,690
-62% -$61.4K ﹤0.01% 1015
2019
Q4 		$102K Sell
36,559
-3,141
-8% -$5.08K ﹤0.01% 1424
2019
Q3 		$61K Buy
+39,700
New +$68.4K ﹤0.01% 1269

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's ABUS Position: Q2 2026 in Review

Michael Gelband sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 23,554 shares — an estimated $106K sold.

Michael Gelband first reported a position in ABUS in Q3 2019 and held it in 13 quarters. The position peaked at $533K in Q1 2021. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Michael Gelband reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 23,554 Arbutus Biopharma shares in Q2 2026, an estimated $106K.
  • Michael Gelband first reported a position in Arbutus Biopharma in Q3 2019 and held it in 13 quarters.
  • Michael Gelband's Arbutus Biopharma position peaked at $533K in Q1 2021.
  • 175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.